Figure 1 | Scientific Reports

Figure 1

From: Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission

Figure 1

Remission maintenance rate and treatments. (A) All patients (n = 36, solid line) with 95% confidence intervals (dotted lines). (B) Comparison of patients discontinuing TNFi (n = 26, solid line) and non-TNFi (n = 8, dotted line). (C) Comparison of patients discontinuing first bDMARD (n = 24, solid line) and second or third bDMARD (n = 10, dotted line). (D) Comparison of patients with concomitant MTX (n = 23, solid line) and without MTX (n = 11, dotted line). TNFi tumour necrosis factor inhibitors, bDMARD biological disease-modifying antirheumatic drug, MTX methotrexate.

Back to article page